Breaks Categories: News

WednesdayJul 12, 2017 12:06 pm

CannabisNewsBreaks – ABcann Global Corporation (TSXV: ABCN) (OTC: ABCCF) Lists Common Shares on OTCQB Venture Market and Frankfurt Stock Exchange

ABcann Global Corporation (TSXV: ABCN) (OTC: ABCCF) this morning announced that its common shares have been approved for trading on the OTCQB Venture Market, under the symbol ‘ABCCF’, and on the Frankfurt Stock Exchange, under the symbol ‘23Q’. The company’s common shares will also continue to trade on the TSX Venture Exchange under the symbol ‘ABCN’. The company expects that these listings will provide a number of long-term benefits, including greater visibility and convenience for investors in the United States and Europe. As a result of this expanded base of potential shareholders, ABcann will likely benefit from enhanced liquidity moving…

Continue Reading

MondayJul 10, 2017 10:09 am

CannabisNewsBreaks – ABcann Global Corporation (TSXV: ABCN) Enters Definitive Agreement for $15 Million Investment

ABcann Global Corporation (TSXV: ABCN) this morning announced the signing of a definitive subscription agreement with Cannabis Wheaton Income Corp. (TSXV: CBW). Under the terms of the deal, Cannabis Wheaton has agreed to purchase $15 million of ABcann common shares at an agreed-upon valuation of $2.25 per share. Completion of this first subscription, which forms part of a larger phased investment by Cannabis Wheaton, is expected to occur by July 31, 2017, subject to customary closing conditions. “We are pleased to move forward with the initial funding phase of our partnership with Cannabis Wheaton and to welcome them as new…

Continue Reading

MondayJul 10, 2017 9:11 am

CannabisNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Enters Research and Development Collaboration with ATERA SAS

Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced its entry into a research and development collaboration with ATERA SAS of France, a leading tissue engineering company specializing in the development of advanced human tissue models. Under the terms of the agreement, ATERA will develop 3D human skin models of Epidermolysis Bullosa (EB) to be used in the evaluation of INM-750, InMed’s proprietary topical cannabinoid product candidate targeted as a therapy in EB and other potential dermatological and wound-healing applications. “INM-750 has demonstrated significant potential in pre-clinical models to address symptomatic improvement of EB including…

Continue Reading

ThursdayJul 06, 2017 10:21 am

CannabisNewsBreaks – ABcann Global Corporation (TSXV: ABCN) Included in the Horizons Medical Marijuana Life Sciences ETF

ABcann Global Corporation (TSXV: ABCN) yesterday announced its inclusion in the Horizons Medical Marijuana Life Sciences ETF (TSX: HMMJ). The ETF is a first-of-its-kind index offering investors direct exposure to a basket of North American life sciences companies with significant business activities in the medical marijuana sector. “The Horizons ETF represents a new type of investment, a fund that tracks an industry in which there is considerable interest but which had no prior investment vehicle through which investors could gain broad exposure,” Aaron Keay, CEO of ABcann, stated in the news release. “Our inclusion in the ETF represents an important…

Continue Reading

FridayJun 30, 2017 11:46 am

CannabisNewsBreaks – ABcann Global Corporation (TSXV: ABCN) Announces Appointment of Dr. Michael Shannon as Chief Medical Consultant

On Thursday, ABcann Global Corporation (TSXV: ABCN) announced that it has retained the services of Dr. Michael Shannon as its chief medical consultant. Shannon brings decades of health care experience to the ABcann team, including time in both the private and public sectors. Among Shannon’s career highlights, in 1996, he assumed responsibilities within Health Canada for re-organizing the Canadian blood system and the development of a new corporate entity dedicated exclusively to the management of blood services in Canada. In 2000, he entered the private sector, simultaneously directing a phase III clinical trial in Canada, the United States and Great…

Continue Reading

MondayJun 26, 2017 9:48 am

CannabisNewsBreaks – ABcann Global Corporation (TSXV: ABCN) Extends University of Guelph Research Agreement through 2018

ABcann Global Corporation (TSXV: ABCN) this morning announced that it has amended and extended the research contract currently in place between its Canadian operating subsidiary, ABcann Medicinals Inc., and the University of Guelph in Ontario, Canada. The agreement, which is focused on controlled environment production of medicinal cannabis, now extends to December 31, 2018, and offers an option to extend further if mutually agreed upon. “ABcann has pursued a unique approach to controlled environment production of cannabis designed to standardize the production and quality of medical compounds,” Dr. Michael Dixon, director of the Controlled Environment Systems Research Facility at the…

Continue Reading

TuesdayJun 13, 2017 9:00 am

CannabisNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Teams with Pharmaseed to Advance Development of INM-750

Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced its entry into an agreement with Pharmaseed Ltd., Israel’s largest GLP-certified pre-clinical contract research organization. Under the terms of this agreement, the Pharmaseed development team will now play a key role in the ongoing development of InMed’s lead compound, INM-750, which is a proprietary, topical cannabinoid product candidate that’s currently being studied as a therapy in epidermolysis bullosa and other potential dermatological and wound-healing applications. “This agreement with Pharmaseed now adds one of Israel's leading formulation development teams to our efforts and represents an important strategic…

Continue Reading

WednesdayMay 31, 2017 10:55 am

CannabisNewsBreaks – Cannabis Wheaton (TSXV: CBW) to Invest $30M in ABcann Global Corporation (TSXV: ABCN) for Construction of Additional Cannabis Cultivation Facility

Medical cannabis grower ABcann Global (TSXV: ABCN) is set to receive an investment of $30 million from Cannabis Wheaton Income (TSXV: CBW) for the funding of a 50,000-square-foot cultivation space at ABcann’s proposed facility to be located in Napanee, Ontario. Per a binding interim agreement announced earlier this week, Cannabis Wheaton’s investment will fund the construction of an “expansion production area” that is in addition to ABcann’s 100,000-square foot-facility, which is expected to commence construction “imminently.” Cannabis Wheaton will receive 50% of the proceeds (net of certain costs) of future wholesale or retail sales completed by ABcann with respect to…

Continue Reading

WednesdayMay 10, 2017 1:58 pm

CannabisNewsBreaks – ABcann Global Corporation (TSXV: ABCN) Extends Role of “Father of Marijuana Research” Raphael Mechoulam

In a news release issued early Tuesday, ABcann Global Corporation (TSXV: ABCN) announced that Raphael Mechoulam has agreed to extend his role as an advisor to the company. Aaron Keay, CEO and director of ABcann, spoke to the importance of this agreement in the news release. “Professor Mechoulam’s experience in medicinal cannabis is an invaluable resource for ABcann as we enter the most aggressive growth stage in the company’s history,” he stated. “The Company has invested heavily to build and extend its early leadership in advanced pharmaceutical-grade cannabis production. Professor Mechoulam’s advice, guidance, and unmatched expertise in the field has…

Continue Reading

FridaySep 23, 2016 1:19 pm

Laguna Blends, Inc. (LAG) (LAGBF) (LB6A.F) Joins Canadian Securities Exchange Composite Index

Laguna Blends Inc. (CSE: LAG) (OTC: LAGBF) (Frankfurt: LB6A.F) this morning announced its inclusion to the CSE Composite index, reflecting the network marketing company’s aggressive expansion strategy. "Inclusion in the CSE Composite index is another indicator Laguna continues to deliver shareholder value through its strategic growth strategy. Laguna has positioned itself to be a dominant player in the distribution and marketing of unique hemp and CBD related products around the world," Bryan Loree, CFO of Laguna Blends, stated in the news release. Laguna Blends uses a network of independent affiliates to market its hemp-based functional beverages, and is exclusively licensed…

Continue Reading